Investigational Drug Information for AZD1390
✉ Email this page to a colleague
What is the development status for investigational drug AZD1390?
AZD1390 is an investigational drug.
There have been 5 clinical trials for AZD1390.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 10th 2017.
The most common disease conditions in clinical trials are Neoplasms, Glioblastoma, and Glioma. The leading clinical trial sponsors are AstraZeneca, University of Leeds, and Beatson West of Scotland Cancer Centre.
There are two US patents protecting this investigational drug and forty-seven international patents.
Summary for AZD1390
| US Patents | 2 |
| International Patents | 47 |
| US Patent Applications | 19 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 1 (2017-10-10) |
| Vendors | 40 |
Recent Clinical Trials for AZD1390
| Title | Sponsor | Phase |
|---|---|---|
| A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer | AstraZeneca | Phase 1 |
| A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Phase 0 Plus Expansion Study of AZD1390 in Recurrent GBM Patients | AstraZeneca | Early Phase 1 |
Clinical Trial Summary for AZD1390
Top disease conditions for AZD1390
Top clinical trial sponsors for AZD1390
US Patents for AZD1390
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AZD1390 | ⤷ Sign Up | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | AstraZeneca AB (Sodertalje, SE) | ⤷ Sign Up |
| AZD1390 | ⤷ Sign Up | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | AstraZeneca AB (Sodertalje, SE) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AZD1390
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AZD1390 | Argentina | AR106053 | 2035-09-17 | ⤷ Sign Up |
| AZD1390 | Australia | AU2016323399 | 2035-09-17 | ⤷ Sign Up |
| AZD1390 | Canada | CA2997399 | 2035-09-17 | ⤷ Sign Up |
| AZD1390 | Chile | CL2018000677 | 2035-09-17 | ⤷ Sign Up |
| AZD1390 | China | CN108137576 | 2035-09-17 | ⤷ Sign Up |
| AZD1390 | Colombia | CO2018002829 | 2035-09-17 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
